Pharmacokinetics of Low Dose Aminoglutethimide in Breast Cancer Patients
Author Information
Author(s): R. Stuart-Harris, I. Bradbrook, P. Morrison, I.E. Smith, H.J. Rogers
Primary Institution: The Royal Marsden Hospital
Hypothesis
The study investigates the pharmacokinetics of low dose aminoglutethimide in postmenopausal women with advanced breast cancer.
Conclusion
The study found that increasing doses of aminoglutethimide significantly raised serum levels of the drug and its metabolite.
Supporting Evidence
- Serum aminoglutethimide and N-acetylaminoglutethimide concentrations were measured by high pressure liquid chromatography.
- Each dose increment was accompanied by a significant rise in serum AG and NAG levels.
- The addition of hydrocortisone did not significantly alter serum AG or NAG concentrations.
- NAG concentrations increased significantly more slowly than AG, leading to a decline in the NAG:AG ratio.
Takeaway
This study looked at how a medicine called aminoglutethimide works in women with breast cancer, showing that higher doses lead to more of the medicine in their blood.
Methodology
The study measured serum concentrations of aminoglutethimide and its metabolite in patients receiving increasing doses over several months.
Limitations
The study did not include patients with renal or hepatic dysfunction, which may limit the generalizability of the findings.
Participant Demographics
All participants were postmenopausal women with advanced breast cancer, with a mean age of 64 years.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website